Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman
Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in collaboration with the National Cancer Society of Malaysia (NCSM), has expanded access to blood-based multi-cancer detection through the Early4Life initiative, reaching communities and frontline institutions across Malaysia with close to 300 SPOT-MAS 10 tests delivered to date.
Over the past few weeks, NCSM and Gene Solutions Malaysia have worked together to bring advanced cancer screening closer to groups that may benefit from greater access and awareness. The initiative has included outreach and screening activities at key institutions such as the Ministry of Defence Malaysia (MINDEF) and PDRM Bukit Aman, the Royal Malaysia Police Headquarters.
As the testing partner for Early4Life, Gene Solutions Malaysia supports the initiative with SPOT-MAS 10, a blood-based multi-cancer detection test designed to detect signals associated with 10 common cancer types. SPOT-MAS 10 has been granted U.S. FDA Breakthrough Device Designation, recognizing its potential to address an unmet medical need in cancer detection.
Meanwhile, NCSM continues to play a leading role in driving outreach, education, and screening access efforts on the ground, helping to connect more individuals and institutions with proactive health solutions.
The Early4Life initiative reflects a shared commitment to strengthening cancer awareness and encouraging earlier, more proactive health action. This is especially important as many cancers continue to be diagnosed at later stages, when treatment can become more complex and outcomes may be less favorable.
By making multi-cancer detection more accessible, Gene Solutions Malaysia and NCSM aim to support a future where more individuals are empowered to take charge of their health through timely screening and early detection strategies.
“We are proud to support NCSM and the Early4Life initiative in bringing innovative cancer detection solutions closer to communities and frontline institutions across Malaysia,” said Mr. Lim Chiun Khee, Director of Gene Solutions Malaysia. “Through SPOT-MAS 10, we hope to contribute to greater awareness, improved access, and a more proactive approach to cancer screening.”
The campaign has been made possible through the support of healthcare institutions, community organizations, and partner agencies committed to advancing public health. Gene Solutions Malaysia and NCSM look forward to continuing this journey with partners across Malaysia and beyond, working toward a future where multi-cancer detection is accessible to more people.
For more information about SPOT-MAS 10 and its role in advancing multi-cancer detection strategies, visit:
https://genesolutions.com/our-test/spot-mas
About National Cancer Society Malaysia
The National Cancer Society of Malaysia (NCSM) is Malaysia’s first non-profit cancer organisation that provides education, care, and support services for cancer patients. Over the last 58 years, it has provided comprehensive assistance to patients and caregivers. NCSM helps patients understand and cope with cancer at various stages through its Cancer and Health Screening Clinic, Nuclear Medicine Centre, Resource and Wellness Centre, Adult’s Home of Hope, and Children’s Home of Hope. To learn more about NCSM, please visit www.cancer.org.my.
About SPOT-MAS 10
SPOT-MAS 10 is a blood-based multi-cancer detection test that analyzes tumor-derived signals in the blood to support the detection of 10 common cancer types. The test is designed to complement existing screening strategies and help advance proactive cancer detection approaches.
Important Regulatory Notice
SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance, or authorization.
